Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inflammatory disease in HLA-B27 transgenic rats.
Taurog JD, Maika SD, Satumtira N, Dorris ML, McLean IL, Yanagisawa H, Sayad A, Stagg AJ, Fox GM, Lê O'Brien A, Rehman M, Zhou M, Weiner AL, Splawski JB, Richardson JA, Hammer RE. Taurog JD, et al. Immunol Rev. 1999 Jun;169:209-23. doi: 10.1111/j.1600-065x.1999.tb01317.x. Immunol Rev. 1999. PMID: 10450519 Review.
A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.
Kameda H, Uechi E, Atsumi T, Abud-Mendoza C, Kamei K, Matsumoto T, Ponce de Leon D, Rehman MI, Zhang M, Radominski SC. Kameda H, et al. Among authors: rehman mi. Int J Rheum Dis. 2020 Jul;23(7):876-881. doi: 10.1111/1756-185X.13846. Epub 2020 May 31. Int J Rheum Dis. 2020. PMID: 32476277 Free PMC article. Clinical Trial.
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
Cohen SB, Radominski SC, Kameda H, Kivitz AJ, Tee M, Cronenberger C, Zhang M, Hackley S, Rehman MI, von Richter O, Alten R. Cohen SB, et al. Among authors: rehman mi. BioDrugs. 2020 Apr;34(2):197-207. doi: 10.1007/s40259-019-00403-z. BioDrugs. 2020. PMID: 31939063 Free PMC article. Clinical Trial.
The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product.
McClellan JE, Conlon HD, Bolt MW, Kalfayan V, Palaparthy R, Rehman MI, Kirchhoff CF. McClellan JE, et al. Among authors: rehman mi. Therap Adv Gastroenterol. 2019 Jun 13;12:1756284819852535. doi: 10.1177/1756284819852535. eCollection 2019. Therap Adv Gastroenterol. 2019. PMID: 31223341 Free PMC article. Review.
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
Cohen SB, Alten R, Kameda H, Hala T, Radominski SC, Rehman MI, Palaparthy R, Schumacher K, Schmitt S, Hua SY, Ianos C, Sewell KL. Cohen SB, et al. Among authors: rehman mi. Arthritis Res Ther. 2018 Jul 27;20(1):155. doi: 10.1186/s13075-018-1646-4. Arthritis Res Ther. 2018. PMID: 30053896 Free PMC article. Clinical Trial.
A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
Palaparthy R, Udata C, Hua SY, Yin D, Cai CH, Salts S, Rehman MI, McClellan J, Meng X. Palaparthy R, et al. Among authors: rehman mi. Expert Rev Clin Immunol. 2018 Apr;14(4):329-336. doi: 10.1080/1744666X.2018.1446829. Epub 2018 Mar 12. Expert Rev Clin Immunol. 2018. PMID: 29504427 Clinical Trial.